Lung Cancer Diagnostic And Screening Market Is In Trends by Early Disease Detection
![]() |
Lung Cancer Diagnostic And Screening Market |
Lung cancer diagnostic and screening
involve techniques to detect lung cancer at an early stage, examine its
location and size, determine how far it has spread, and monitor its response to
treatment. Lung cancer diagnostic tools such as low-dose computed tomography
(CT), X-rays, sputum cytology, biomarkers, and imaging tests help identify
cancerous cells in the lungs and determine the stage of cancer. Early diagnosis
significantly improves outcomes and survival rates.
Key players operating in the Lung Cancer Diagnostic And Screening are ExxonMobil, Chevron Phillips Chemical Company, SABIC, China National Petroleum Corporation (CNPC), BASF. These key players are launching advanced diagnostic technologies and participating in collaborations to strengthen their market position. ExxonMobil recently launched a new biomarker test to detect early-stage lung cancer.
The growing prevalence of Lung Cancer Diagnostic And Screening Market Trends awareness regarding early diagnosis is fueling the demand for lung cancer diagnostic and screening services. As per the WHO, lung cancer was the leading cause of cancer deaths in 2018 accounting for over 1.8 million deaths globally. Governments across countries are launching lung cancer screening programs to reduce mortality.
The global lung cancer diagnostic and screening market is expanding rapidly with market players focusing on emerging countries for future growth opportunities. Players are forming partnerships with local diagnostic centers and hospitals in developing nations to boost the availability of advanced diagnostic tests. SABIC partnered with a leading Chinese hospital to launch an early-stage lung cancer screening program in China.
Market Key Trends
Bargaining power of buyers: Large
customer base for lung cancer screening and diagnostic tests resulting in
decrease in bargaining power of individual healthcare providers and patients.
Bargaining power of suppliers:
Availability of substitute products increases supplier's bargaining power.
Threat of new substitutes: Constant
innovations in early lung cancer detection methods emerging as substitutes to
existing tests.
North America accounts for the largest share of the lung cancer diagnostic and screening market owing to rising incidence of lung cancer cases, favourable reimbursement policies and awareness initiatives by healthcare organisations. The region is expected to dominate the global market during the forecast period as well.
Get
More Insights On, Lung
Cancer Diagnostic And Screening Market
Comments
Post a Comment